Reumatologia Clinica最新文献

英文中文

Prevalencia de hidrosadenitis supurativa en pacientes con espondiloartritis axial

IF 1.2 Q4 RHEUMATOLOGY

Reumatologia Clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.reuma.2024.501808

Laura Farran Ortega , Rosa Fornons-Servent , Joan Miquel Nolla , Xavier Juanola Roura

Objectives

To determine the prevalence of hidradenitis suppurativa (HS) in patients with axial spondyloarthritis (AxSpA) and to describe clinical, laboratory, and radiographic characteristics of patients diagnosed with HS.

Patients and methods

We performed a cross-sectional study of a cohort of 265 patients with AxSpA in follow-up at a tertiary hospital. Patients were screened for HS using a questionnaire, with subsequent diagnostic confirmation by a dermatologist. We collected demographic, clinical, laboratory, and radiographic data. Patients were classified by diagnosis of HS. A descriptive analysis and comparison were performed for both groups.

Results

A total of 148 of the 265 patients (55.8%) completed the screening questionnaire. Screening was positive in 9 patients (6.1%), although the diagnosis of HS was confirmed in only 4 (2.7%). Three patients were diagnosed during the study, with a mean diagnostic delay of 14.25 years. All the patients had mild HS (Hurley stage I). When patients with and without HS were compared, the HS group had more smokers (75% vs. 18%; P=.005), greater disease activity according to BASDAI (5.6 ± 2.3 vs. 3.2 ± 2.1; P=.026), less structural damage according to the axial BASRI (1.5 ± 1.3 vs. 5.5 ± 3.5; P<.018) and shorter time since diagnosis of AxSpA (14.7 ± 2.6 vs. 27.8 ± 13.5 years; P=.001). No significant differences were found for the remaining variables studied.

Conclusion

This study suggests that prevalence of HS in patients with AxSpA is higher than the one observed in general population. The knowledge of this association should encourage clinicians to inquire about symptoms of HS and actively search for lesions.

{"title":"Prevalencia de hidrosadenitis supurativa en pacientes con espondiloartritis axial","authors":"Laura Farran Ortega , Rosa Fornons-Servent , Joan Miquel Nolla , Xavier Juanola Roura","doi":"10.1016/j.reuma.2024.501808","DOIUrl":"10.1016/j.reuma.2024.501808","url":null,"abstract":"<div><h3>Objectives</h3><div>To determine the prevalence of hidradenitis suppurativa (HS) in patients with axial spondyloarthritis (AxSpA) and to describe clinical, laboratory, and radiographic characteristics of patients diagnosed with HS.</div></div><div><h3>Patients and methods</h3><div>We performed a cross-sectional study of a cohort of 265 patients with AxSpA in follow-up at a tertiary hospital. Patients were screened for HS using a questionnaire, with subsequent diagnostic confirmation by a dermatologist. We collected demographic, clinical, laboratory, and radiographic data. Patients were classified by diagnosis of HS. A descriptive analysis and comparison were performed for both groups.</div></div><div><h3>Results</h3><div>A total of 148 of the 265 patients (55.8%) completed the screening questionnaire. Screening was positive in 9 patients (6.1%), although the diagnosis of HS was confirmed in only 4 (2.7%). Three patients were diagnosed during the study, with a mean diagnostic delay of 14.25 years. All the patients had mild HS (Hurley stage I). When patients with and without HS were compared, the HS group had more smokers (75% vs. 18%; <em>P</em>=.005), greater disease activity according to BASDAI (5.6±2.3 vs. 3.2±2.1; <em>P</em>=.026), less structural damage according to the axial BASRI (1.5±1.3 vs. 5.5±3.5; <em>P</em><.018) and shorter time since diagnosis of AxSpA (14.7±2.6 vs. 27.8±13.5 years; <em>P</em>=.001). No significant differences were found for the remaining variables studied.</div></div><div><h3>Conclusion</h3><div>This study suggests that prevalence of HS in patients with AxSpA is higher than the one observed in general population. The knowledge of this association should encourage clinicians to inquire about symptoms of HS and actively search for lesions.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 2","pages":"Article 501808"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143386757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of performance of the Still Activity Score for assessment of Adult-onset Still's Disease: Comparative study with Systemic Feature Score and Modified Pouchot-Activity Score

IF 1.2 Q4 RHEUMATOLOGY

Reumatologia Clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.reuma.2024.501814

Emine Uslu , Müçteba Enes Yayla , Didem Şahin-Eroğlu , Büşra Atmaca-Haktaniyan , Nilgün Göveç-Giynaş , Recep Yilmaz , Ahmet İlbay , Abdulbaki Gaydan , Yeter Mahmutoğlu , Ahmet Usta , Tahsin Murat Turgaya , Gülay Kinikli , Aşkın Ateş

Backgrounds

Adult-onset Still's Disease (AOSD) is a systemic inflammatory disorder. There is no definitive AOSD activity indicator. Two of the currently used disease activity scores are the Modified Pouchot Activity Score (mPoS), and Systemic Feature Score (SFS). Another scoring system has been recently introduced, named the Still Activity Score (SAS).

Aims

In this single-center cross-sectional study, we aimed to compare the performance of the SAS with the mPoS and SFS, both of which have been used for a long time for measuring disease activity in patients with AOSD.

Method

69 patients aged 18 or older were screened in the study who attended the Ankara University Faculty of Medicine between 2010 and 2020 with a diagnosis of AOSD. We compared SAS, SFS and mPoS with physician global assessment (PhGA) in patients with AOSD.

Results

Of 69 patients screened, 45 patients with AOSD who fulfilled the Yamaguchi criteria were analyzed. The results showed no significant difference in SAS between patients with PhGA < 6 and PhGA ≥ 6, but mPoS and SFS scores were higher in the PhGA ≥ 6 group (p = 0.053, p = 0.001, p = 0.007, respectively). There was a significant correlation between mPoS and PhGA (p = 0.018).

Conclusion

This is the first study to evaluate the SAS score, which is used for patients with AOSD. SAS is user-friendly but may not be as sensitive as mPoS and SFS for assessing disease activity in AOSD.

{"title":"Evaluation of performance of the Still Activity Score for assessment of Adult-onset Still's Disease: Comparative study with Systemic Feature Score and Modified Pouchot-Activity Score","authors":"Emine Uslu , Müçteba Enes Yayla , Didem Şahin-Eroğlu , Büşra Atmaca-Haktaniyan , Nilgün Göveç-Giynaş , Recep Yilmaz , Ahmet İlbay , Abdulbaki Gaydan , Yeter Mahmutoğlu , Ahmet Usta , Tahsin Murat Turgaya , Gülay Kinikli , Aşkın Ateş","doi":"10.1016/j.reuma.2024.501814","DOIUrl":"10.1016/j.reuma.2024.501814","url":null,"abstract":"<div><h3>Backgrounds</h3><div>Adult-onset Still's Disease (AOSD) is a systemic inflammatory disorder. There is no definitive AOSD activity indicator. Two of the currently used disease activity scores are the Modified Pouchot Activity Score (mPoS), and Systemic Feature Score (SFS). Another scoring system has been recently introduced, named the Still Activity Score (SAS).</div></div><div><h3>Aims</h3><div>In this single-center cross-sectional study, we aimed to compare the performance of the SAS with the mPoS and SFS, both of which have been used for a long time for measuring disease activity in patients with AOSD.</div></div><div><h3>Method</h3><div>69 patients aged 18 or older were screened in the study who attended the Ankara University Faculty of Medicine between 2010 and 2020 with a diagnosis of AOSD. We compared SAS, SFS and mPoS with physician global assessment (PhGA) in patients with AOSD.</div></div><div><h3>Results</h3><div>Of 69 patients screened, 45 patients with AOSD who fulfilled the Yamaguchi criteria were analyzed. The results showed no significant difference in SAS between patients with PhGA<6 and PhGA≥6, but mPoS and SFS scores were higher in the PhGA≥6 group (<em>p</em>  =0.001, <em>p</em>  =0.018).</div></div><div><h3>Conclusion</h3><div>This is the first study to evaluate the SAS score, which is used for patients with AOSD. SAS is user-friendly but may not be as sensitive as mPoS and SFS for assessing disease activity in AOSD.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 2","pages":"Article 501814"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143386809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of the psychometric properties of the Functional Ability Scale in children with juvenile idiopathic arthritis

IF 1.2 Q4 RHEUMATOLOGY

Reumatologia Clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.reuma.2024.10.003

Juan Pablo Ford , Enrique Roberto Soriano , Mauro Andreu

Background and objective

Juvenile idiopathic arthritis (JIA) has a generalized impact on physical function, thus functional capacity (FC) is one of the main outcome measures in this population. FC can be evaluated using self-referential questionnaires and with observational tests such as the Functional Ability Scale (CAPFUN). The psychometric properties of this scale have not been tested yet.

The objective of this study to evaluate the psychometric properties of the CAPFUN in children with JIA according to Consensus-based Standards for the selection of health Measurements Instruments (COSMIN).

Material and methods

Psychometric properties measurement study. Children were admitted between January 2018 and November 2019. Inclusion criteria: age between 6 and 16 years, diagnosis of JIA, complete physical therapy evaluation, including: CAPFUN scale, Childhood Health Assessment Questionnaire (C-HAQ), Visual Numerical Scale of patient's self-perceived Functional Capacity (VNSFC), Global Rating of Change (GROC) scale and Steinbrocker Scale. Subjects who discontinued follow-up were excluded. The psychometric properties evaluated were: reliability, construct validity, responsiveness, and interpretability.

Results

A total of 114 children were analyzed. The internal consistency was acceptable, as indicated by a Cronbach alpha of 0.93. Test–retest reliability showed a high level of consistency with an intraclass correlation coefficient of 0.999 (95% CI: 0.998–0.999). Regarding structural validity, the exploratory factor analysis yielded acceptable results, demonstrating the reliability of the instrument. All correlation coefficients were strong and all predetermined hypotheses were verified. The minimal clinically important difference was 0.04. [AUC 0.90 (95% CI: 0.83–0.91)].

Conclusions

The evaluations of the psychometric properties of the CAPFUN were satisfactory, demonstrating acceptable values for reliability, construct validity, responsiveness, and interpretability. Based on these results, this tool can effectively assess FC in children with JIA, both in clinical practice and research contexts.

{"title":"Evaluation of the psychometric properties of the Functional Ability Scale in children with juvenile idiopathic arthritis","authors":"Juan Pablo Ford , Enrique Roberto Soriano , Mauro Andreu","doi":"10.1016/j.reuma.2024.10.003","DOIUrl":"10.1016/j.reuma.2024.10.003","url":null,"abstract":"<div><h3>Background and objective</h3><div>Juvenile idiopathic arthritis (JIA) has a generalized impact on physical function, thus functional capacity (FC) is one of the main outcome measures in this population. FC can be evaluated using self-referential questionnaires and with observational tests such as the Functional Ability Scale (CAPFUN). The psychometric properties of this scale have not been tested yet.</div><div>The objective of this study to evaluate the psychometric properties of the CAPFUN in children with JIA according to Consensus-based Standards for the selection of health Measurements Instruments (COSMIN).</div></div><div><h3>Material and methods</h3><div>Psychometric properties measurement study. Children were admitted between January 2018 and November 2019. Inclusion criteria: age between 6 and 16 years, diagnosis of JIA, complete physical therapy evaluation, including: CAPFUN scale, Childhood Health Assessment Questionnaire (C-HAQ), Visual Numerical Scale of patient's self-perceived Functional Capacity (VNSFC), Global Rating of Change (GROC) scale and Steinbrocker Scale. Subjects who discontinued follow-up were excluded. The psychometric properties evaluated were: reliability, construct validity, responsiveness, and interpretability.</div></div><div><h3>Results</h3><div>A total of 114 children were analyzed. The internal consistency was acceptable, as indicated by a Cronbach alpha of 0.93. Test–retest reliability showed a high level of consistency with an intraclass correlation coefficient of 0.999 (95% CI: 0.998–0.999). Regarding structural validity, the exploratory factor analysis yielded acceptable results, demonstrating the reliability of the instrument. All correlation coefficients were strong and all predetermined hypotheses were verified. The minimal clinically important difference was 0.04. [AUC 0.90 (95% CI: 0.83–0.91)].</div></div><div><h3>Conclusions</h3><div>The evaluations of the psychometric properties of the CAPFUN were satisfactory, demonstrating acceptable values for reliability, construct validity, responsiveness, and interpretability. Based on these results, this tool can effectively assess FC in children with JIA, both in clinical practice and research contexts.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 2","pages":"Article 101802"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143386810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comorbidities in Mexican Mestizo patients with rheumatoid arthritis: A cross-sectional study of 523 patients in a preventive cardio-rheumatology clinic

IF 1.2 Q4 RHEUMATOLOGY

Reumatologia Clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.reuma.2024.501813

Rosa I. Arvizu-Rivera , Jesus A. Cardenas-de la Garza , Valeria Gonzalez-Gonzalez , Dionicio A. Galarza-Delgado , Jose R. Azpiri-Lopez , Andrea L. Guajardo-Aldaco , Maria F. Elizondo-Benitez , Iris J. Colunga-Pedraza

Objective

The aim of this study was to determine the prevalence of cardiovascular risk factors and comorbidities in a cohort of Mexican Mestizo rheumatoid arthritis (RA) patients.

Methods

We performed an observational and cross-sectional study involving the RA cohort of our Cardio-Rheumatology Clinic in a teaching hospital. The cohort includes patients aged 40–75 years old who fulfilled the ACR/EULAR classification criteria for RA, patients were recruited from August 2014 to July 2023. Cardiovascular risk factors and comorbidities were defined as a diagnosis included in the patient's medical record or the use of treatment for these conditions.

Results

523 patients with RA were included; the majority were women (92.3%). The median age was 55 (48.9–61.0) years. The most prevalent cardiovascular risk factors were overweight (219, 42%), obesity (157, 32.0%), dyslipidemia (165, 31.5%), and hypertension (164, 31.3%). We also detected, that 12.1% of patients without a diagnosis of hypertension had elevated blood pressure, hyperglycemia was reported in 17.2%, and lipid profile alterations were present in 70.6% of patients with no previous diagnosis of type 2 diabetes mellitus and dyslipidemia, respectively.

Conclusion

Cardiovascular risk factors are prevalent in patients with rheumatoid arthritis. Overweight, obesity, and dyslipidemia were the most prevalent cardiovascular risk factors in our cohort. Alterations in the lipid profile were reported in half of the patients with no previous diagnosis of dyslipidemia.

{"title":"Comorbidities in Mexican Mestizo patients with rheumatoid arthritis: A cross-sectional study of 523 patients in a preventive cardio-rheumatology clinic","authors":"Rosa I. Arvizu-Rivera , Jesus A. Cardenas-de la Garza , Valeria Gonzalez-Gonzalez , Dionicio A. Galarza-Delgado , Jose R. Azpiri-Lopez , Andrea L. Guajardo-Aldaco , Maria F. Elizondo-Benitez , Iris J. Colunga-Pedraza","doi":"10.1016/j.reuma.2024.501813","DOIUrl":"10.1016/j.reuma.2024.501813","url":null,"abstract":"<div><h3>Objective</h3><div>The aim of this study was to determine the prevalence of cardiovascular risk factors and comorbidities in a cohort of Mexican Mestizo rheumatoid arthritis (RA) patients.</div></div><div><h3>Methods</h3><div>We performed an observational and cross-sectional study involving the RA cohort of our Cardio-Rheumatology Clinic in a teaching hospital. The cohort includes patients aged 40–75 years old who fulfilled the ACR/EULAR classification criteria for RA, patients were recruited from August 2014 to July 2023. Cardiovascular risk factors and comorbidities were defined as a diagnosis included in the patient's medical record or the use of treatment for these conditions.</div></div><div><h3>Results</h3><div>523 patients with RA were included; the majority were women (92.3%). The median age was 55 (48.9–61.0) years. The most prevalent cardiovascular risk factors were overweight (219, 42%), obesity (157, 32.0%), dyslipidemia (165, 31.5%), and hypertension (164, 31.3%). We also detected, that 12.1% of patients without a diagnosis of hypertension had elevated blood pressure, hyperglycemia was reported in 17.2%, and lipid profile alterations were present in 70.6% of patients with no previous diagnosis of type 2 diabetes mellitus and dyslipidemia, respectively.</div></div><div><h3>Conclusion</h3><div>Cardiovascular risk factors are prevalent in patients with rheumatoid arthritis. Overweight, obesity, and dyslipidemia were the most prevalent cardiovascular risk factors in our cohort. Alterations in the lipid profile were reported in half of the patients with no previous diagnosis of dyslipidemia.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 2","pages":"Article 501813"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143386759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Seguridad de terapias biológicas y sintéticas dirigidas en pacientes con enfermedades inmunomediadas: datos del registro BIOBADAGUAY

IF 1.2 Q4 RHEUMATOLOGY

Reumatologia Clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.reuma.2024.09.008

Paloma de Abreu , Sonia Cabrera , Darwin Cordovilla , Lourdes Román , Cristina Brunengo , Patricia Melgarejo , Macarena Soto , Vannia Valinotti , Angelica Amarilla , Belem Acevedo , Alexis Pineda , Evelyn Leiva , Paola Pusineri , Sandra Consani , Mariela Zarza , Clyde Parodi , Zoilo Morel , Roger Rolón , Paola Jara , Raquel Aranda , Gabriela Ávila

Objective

To analyze the safety of biologic (DMARDs-b) and synthetic targeted therapies (DMARDs-sd) in the BIOBADAGUAY registry (Paraguayan-Uruguayan registry of adverse events (AEs) in patients with inflammatory rheumatic diseases).

Methods

BIOBADAGUAY is a registry to prospectively evaluate the efficacy and safety of FAME-b and FAME-sd. The full methodology is available at https://biobadaguay.ser.es. Variables associated with the safety of the therapies were used for the present study. The incidence of AA was calculated as incidence rate (IR) per 1000 patient-years, with 95% confidence intervals (CI) and Poisson regression for the incidence rate ratio (IRR).

Results

1104 patients (73.3% female) with 1366 AA, predominantly mild (87.2%), were analyzed. The overall incidence of AEs was 251.75 per 1000 patient-years. Infections were the most frequent (55.0%), with an incidence of 138.4 per 1000 patient-years. Rheumatoid arthritis and corticosteroid use were associated with more global AEs, while anti-TNF was associated with less AEs.

Conclusions

This study from the BIOBADAGUAY registry has provided valuable data on the safety of DMARD-b, sd in a cohort of patients with inflammatory rheumatic diseases. The incidence of predominantly mild AEs, with infections as the most frequent adverse event, underscores the need for rigorous and constant monitoring in this population.

{"title":"Seguridad de terapias biológicas y sintéticas dirigidas en pacientes con enfermedades inmunomediadas: datos del registro BIOBADAGUAY","authors":"Paloma de Abreu , Sonia Cabrera , Darwin Cordovilla , Lourdes Román , Cristina Brunengo , Patricia Melgarejo , Macarena Soto , Vannia Valinotti , Angelica Amarilla , Belem Acevedo , Alexis Pineda , Evelyn Leiva , Paola Pusineri , Sandra Consani , Mariela Zarza , Clyde Parodi , Zoilo Morel , Roger Rolón , Paola Jara , Raquel Aranda , Gabriela Ávila","doi":"10.1016/j.reuma.2024.09.008","DOIUrl":"10.1016/j.reuma.2024.09.008","url":null,"abstract":"<div><h3>Objective</h3><div>To analyze the safety of biologic (DMARDs-b) and synthetic targeted therapies (DMARDs-sd) in the BIOBADAGUAY registry (Paraguayan-Uruguayan registry of adverse events (AEs) in patients with inflammatory rheumatic diseases).</div></div><div><h3>Methods</h3><div>BIOBADAGUAY is a registry to prospectively evaluate the efficacy and safety of FAME-b and FAME-sd. The full methodology is available at <span><span>https://biobadaguay.ser.es</span><svg><path></path></svg></span>. Variables associated with the safety of the therapies were used for the present study. The incidence of AA was calculated as incidence rate (IR) per 1000 patient-years, with 95% confidence intervals (CI) and Poisson regression for the incidence rate ratio (IRR).</div></div><div><h3>Results</h3><div>1104 patients (73.3% female) with 1366 AA, predominantly mild (87.2%), were analyzed. The overall incidence of AEs was 251.75 per 1000 patient-years. Infections were the most frequent (55.0%), with an incidence of 138.4 per 1000 patient-years. Rheumatoid arthritis and corticosteroid use were associated with more global AEs, while anti-TNF was associated with less AEs.</div></div><div><h3>Conclusions</h3><div>This study from the BIOBADAGUAY registry has provided valuable data on the safety of DMARD-b, sd in a cohort of patients with inflammatory rheumatic diseases. The incidence of predominantly mild AEs, with infections as the most frequent adverse event, underscores the need for rigorous and constant monitoring in this population.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 2","pages":"Article 101798"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143387377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enfermedades reumatológicas en pacientes con hepatitis autoinmune en un hospital de cuarto nivel de Bogotá entre el 2013 al 2023

IF 1.2 Q4 RHEUMATOLOGY

Reumatologia Clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.reuma.2024.501812

Juan Sebastián Almánzar Cortés , Cathalina Vergara Cabra , María Paula Uchima-Vera , Gerardo Quintana , Fernando Sierra

Introduction

Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease with low prevalence worldwide. The coexistence of this entity with rheumatic diseases has been evaluated in multiple studies and is highly variable. The objective of this study is to identify the frequency of coexistence of rheumatic diseases and autoimmune hepatitis in adults who have been treated for 10 years in a fourth-level hospital in Bogota, Colombia.

Materials and methods

Analytical, observational, cross-sectional study in a single center that included patients over 18 years of age of both sexes with a diagnosis of AIH by simplified score ≥ 7 points, with a medical history registered at the Fundacion Santa Fe de Bogota in Bogota, Colombia, between January 2013 and December 2023.

Results

A total of 66 patients met inclusion criteria. 36.4% of patients had a concomitant autoimmune disease, with Sjögren's syndrome, systemic lupus erythematosus and autoimmune thyroid disease being the most prevalent.

Conclusion

The frequency of coexistence of autoimmune hepatitis with rheumatic diseases in adult patients is 36.4% for the cohort studied, which is within the range of what has already been reported globally, where a prevalence of 14 to 44% has been described.

{"title":"Enfermedades reumatológicas en pacientes con hepatitis autoinmune en un hospital de cuarto nivel de Bogotá entre el 2013 al 2023","authors":"Juan Sebastián Almánzar Cortés , Cathalina Vergara Cabra , María Paula Uchima-Vera , Gerardo Quintana , Fernando Sierra","doi":"10.1016/j.reuma.2024.501812","DOIUrl":"10.1016/j.reuma.2024.501812","url":null,"abstract":"<div><h3>Introduction</h3><div>Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease with low prevalence worldwide. The coexistence of this entity with rheumatic diseases has been evaluated in multiple studies and is highly variable. The objective of this study is to identify the frequency of coexistence of rheumatic diseases and autoimmune hepatitis in adults who have been treated for 10years in a fourth-level hospital in Bogota, Colombia.</div></div><div><h3>Materials and methods</h3><div>Analytical, observational, cross-sectional study in a single center that included patients over 18years of age of both sexes with a diagnosis of AIH by simplified score ≥7points, with a medical history registered at the Fundacion Santa Fe de Bogota in Bogota, Colombia, between January 2013 and December 2023.</div></div><div><h3>Results</h3><div>A total of 66 patients met inclusion criteria. 36.4% of patients had a concomitant autoimmune disease, with Sjögren's syndrome, systemic lupus erythematosus and autoimmune thyroid disease being the most prevalent.</div></div><div><h3>Conclusion</h3><div>The frequency of coexistence of autoimmune hepatitis with rheumatic diseases in adult patients is 36.4% for the cohort studied, which is within the range of what has already been reported globally, where a prevalence of 14 to 44% has been described.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 2","pages":"Article 501812"},"PeriodicalIF":1.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143386758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perforación ileal terminal no traumática en un paciente con reumatismo palindrómico refractario tratado con sarilumab: reporte de caso

IF 1.2 Q4 RHEUMATOLOGY

Reumatologia Clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.reuma.2024.501811

Anastasia Mocritcaia , Rocío García-Pérez , Beatriz Frade , Raimon Sanmartí

Intestinal perforation, a rare complication of interleukin (IL)-6 therapy for immune-mediated diseases (mainly rheumatoid arthritis), typically manifests in the lower gastrointestinal tract, often in association with prior history of diverticulitis. Patients may present with acute abdominal pain and suspicion for this complication should remain high even in the absence of elevated C-reactive protein. We describe a 69-year-old female patient with a history of resistant seropositive palindromic rheumatism treated with sarilumab who developed a nontraumatic terminal ileal perforation.

引用次数: 0

Investigating potential biomarkers and therapeutic targets for patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) through the utilization of cytokine profiling

IF 1.2 Q4 RHEUMATOLOGY

Reumatologia Clinica

Pub Date : 2025-01-01 DOI: 10.1016/j.reuma.2024.10.006

Akhil Akhil , Rohit Bansal , Jyotsana Kaushal , Aman Sharma , Archana Bhatnagar

Objectives

Examining cytokine profile complexities in chronic autoimmune disorders holds significant clinical importance. In order to address the similarities and differences related to SLE and RA, it was necessary to evaluate their cytokine chemokine profiles. Such analyses would give pointers towards differences, leading thereby to explore the potential of cytokines/chemokines as biomarkers. The study was therefore driven by the concept of understanding the major differences at this level with a hope of contribution towards diagnostics/theranostics. A multiplex study was carried out on systemic autoimmune disorders, such as SLE and RA, analysing forty analytes in comparison with healthy controls.

Methodology

Age and sex matched healthy donors and patients (n = 38) were recruited and plasma cytokine profiling was done by Bio-plex multiplex immunoassay system.

Results

A comparison with healthy volunteers revealed differential alteration in various chemokines in SLE and RA, respectively. Protein interaction analysis identified a core complex of chemokines (CXCL10, CCL5, CXCL12, CXCL9, CXCL1, and CXCL27) as central modulators, suggesting their potential as biomarkers. Drug prediction using the DSigDB database identified acetovanillone as a potential drug against this core complex. In comparing lupus patients with or without arthritis comorbidity, elevated levels of cytokines: IL-12, SCF, and TNF-a were prominently associated with arthritis in SLE. TNF-a emerged as a potential indicator specifically for arthritis.

Conclusion

This study enhances our understanding of the complex interplay of cytokine/chemokine in these systemic conditions and suggests their utility as targets and diagnostic paradigms for detection.

{"title":"Investigating potential biomarkers and therapeutic targets for patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) through the utilization of cytokine profiling","authors":"Akhil Akhil , Rohit Bansal , Jyotsana Kaushal , Aman Sharma , Archana Bhatnagar","doi":"10.1016/j.reuma.2024.10.006","DOIUrl":"10.1016/j.reuma.2024.10.006","url":null,"abstract":"<div><h3>Objectives</h3><div>Examining cytokine profile complexities in chronic autoimmune disorders holds significant clinical importance. In order to address the similarities and differences related to SLE and RA, it was necessary to evaluate their cytokine chemokine profiles. Such analyses would give pointers towards differences, leading thereby to explore the potential of cytokines/chemokines as biomarkers. The study was therefore driven by the concept of understanding the major differences at this level with a hope of contribution towards diagnostics/theranostics. A multiplex study was carried out on systemic autoimmune disorders, such as SLE and RA, analysing forty analytes in comparison with healthy controls.</div></div><div><h3>Methodology</h3><div>Age and sex matched healthy donors and patients (<em>n</em>  <!-->38) were recruited and plasma cytokine profiling was done by Bio-plex multiplex immunoassay system.</div></div><div><h3>Results</h3><div>A comparison with healthy volunteers revealed differential alteration in various chemokines in SLE and RA, respectively. Protein interaction analysis identified a core complex of chemokines (CXCL10, CCL5, CXCL12, CXCL9, CXCL1, and CXCL27) as central modulators, suggesting their potential as biomarkers. Drug prediction using the DSigDB database identified acetovanillone as a potential drug against this core complex. In comparing lupus patients with or without arthritis comorbidity, elevated levels of cytokines: IL-12, SCF, and TNF-a were prominently associated with arthritis in SLE. TNF-a emerged as a potential indicator specifically for arthritis.</div></div><div><h3>Conclusion</h3><div>This study enhances our understanding of the complex interplay of cytokine/chemokine in these systemic conditions and suggests their utility as targets and diagnostic paradigms for detection.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 1","pages":"Article 101805"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143304892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Análisis bibliométrico de la producción científica de los servicios de reumatología en España en el período 2013-2022

IF 1.2 Q4 RHEUMATOLOGY

Reumatologia Clinica

Pub Date : 2025-01-01 DOI: 10.1016/j.reuma.2024.10.008

Daniel Seoane-Mato , Fernando Sánchez-Alonso , Mercedes Guerra-Rodríguez , Enrique González-Dávila , Federico Díaz-González

Background and objective

Bibliometric studies of scientific production in Spanish Rheumatology are scarce. The aim of this study was to analyze the bibliographic production of rheumatology services in Spain over the period 2013-2022.

Materials and methods

Original articles and reviews with the affiliation of the first or corresponding author to a Spanish rheumatology service/department/section/unit were identified in the Web of Science Core Collection and Scopus databases. Keywords and titles were used to classify articles by field (clinical, epidemiological or basic) and pathology. International collaborations and collaborations between Autonomous Communities (AC) were identified. Quantitative bibliometric indicators were obtained (number of articles published per year, pathology and AC) and impact indicators were obtained (based on the number of citations per article). The H-index was also calculated.

Results

The total number of publications was 2321, with an annual growth rate of 4.1% in the period analyzed. In 14.1% of the articles there were international collaborations, mainly with the United States and the United Kingdom, while between ACs the most numerous were between Madrid and Catalonia. The pathologies with the highest H-index were rheumatoid arthritis (RA), spondyloarthropathies (SpA), osteoarthritis and vasculitis (34, 32, 28 and 26, respectively). The H-index for the Spanish rheumatology services as a whole was 69.

Discussion and conclusions

The scientific production of rheumatology services/departments/sections/units in our country increased between 2013 and 2022. By pathology, the scientific production in RA and SpA stands out.

{"title":"Análisis bibliométrico de la producción científica de los servicios de reumatología en España en el período 2013-2022","authors":"Daniel Seoane-Mato , Fernando Sánchez-Alonso , Mercedes Guerra-Rodríguez , Enrique González-Dávila , Federico Díaz-González","doi":"10.1016/j.reuma.2024.10.008","DOIUrl":"10.1016/j.reuma.2024.10.008","url":null,"abstract":"<div><h3>Background and objective</h3><div>Bibliometric studies of scientific production in Spanish Rheumatology are scarce. The aim of this study was to analyze the bibliographic production of rheumatology services in Spain over the period 2013-2022.</div></div><div><h3>Materials and methods</h3><div>Original articles and reviews with the affiliation of the first or corresponding author to a Spanish rheumatology service/department/section/unit were identified in the Web of Science Core Collection and Scopus databases. Keywords and titles were used to classify articles by field (clinical, epidemiological or basic) and pathology. International collaborations and collaborations between Autonomous Communities (AC) were identified. Quantitative bibliometric indicators were obtained (number of articles published per year, pathology and AC) and impact indicators were obtained (based on the number of citations per article). The H-index was also calculated.</div></div><div><h3>Results</h3><div>The total number of publications was 2321, with an annual growth rate of 4.1% in the period analyzed. In 14.1% of the articles there were international collaborations, mainly with the United States and the United Kingdom, while between ACs the most numerous were between Madrid and Catalonia. The pathologies with the highest H-index were rheumatoid arthritis (RA), spondyloarthropathies (SpA), osteoarthritis and vasculitis (34, 32, 28 and 26, respectively). The H-index for the Spanish rheumatology services as a whole was 69.</div></div><div><h3>Discussion and conclusions</h3><div>The scientific production of rheumatology services/departments/sections/units in our country increased between 2013 and 2022. By pathology, the scientific production in RA and SpA stands out.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"21 1","pages":"Article 101807"},"PeriodicalIF":1.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143304895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efecto de la liraglutida en pacientes con artritis psoriásica y obesidad

IF 1.2 Q4 RHEUMATOLOGY

Reumatologia Clinica

Pub Date : 2025-01-01 DOI: 10.1016/j.reuma.2024.501809

Joana Nicolau , Antoni Nadal , Inmaculada Ros , Lluís Masmiquel

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Reumatologia Clinica

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀